NCT06678659Phase 1, phase 2Recruiting

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Study sponsor: Recursion Pharmaceuticals Inc. · RXRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-07Estimated
Enrollment · participants310Estimated
Source updated2026-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.